Globus Medical’s first quarter delivered results ahead of Wall Street’s expectations, but the market reacted negatively, with shares declining over 5%. Manag...
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory de...
Globus Medical (NYSE:GMED) reported a strong start to 2026, with first-quarter revenue and earnings rising sharply as the company cited continued momentum in U.S. spine, margin expansion and contributions from its Nevro acquisition.
President and Chief Executive Officer Keith Pfeil said the company
Medical device company Globus Medical (NYSE:GMED) announced better-than-expected revenue in Q1 CY2026, with sales up 27% year on year to $759.9 million. The ...
Medical device company Globus Medical (NYSE:GMED) beat Wall Street’s revenue expectations in Q1 CY2026, with sales up 27% year on year to $759.9 million. The...
Medical device company Globus Medical (NYSE:GMED) will be reporting earnings this Thursday afternoon. Here’s what you need to know. Globus Medical beat analy...
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how medical devices &...
A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face c...
What a fantastic six months it’s been for Globus Medical. Shares of the company have skyrocketed 62.5%, hitting $94.80. This was partly thanks to its solid q...
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ...
What Happened? A number of stocks fell in the afternoon session after major indices including the S&P 500 and Dow Jones Industrial Average fell sharply as in...
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...
Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market va...
